Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06170619 · ClinicalTrials.gov registry record
Obsidio™ Conformable Embolic Registry
A clinical trial of Bleeding and Hemorrhage, sponsored by Boston Scientific Corporation.
- Completed
- Registry status
- 125
- Enrollment target
- 20
- Study locations
NCT06170619 is a study of Bleeding and Hemorrhage that has completed, run by Boston Scientific Corporation. The registered enrollment target is 125 participants, below the 1,479-participant average among 23 other Bleeding trials with a reported enrollment target (92% lower). The trial reports 20 study locations across 15 states.
The verdict
NCT06170619, a study of Bleeding and Hemorrhage, has completed, sponsored by Boston Scientific Corporation.
- COMPLETED
- Registry status
- 125 participants
- Enrollment target
- 20
- Study locations
Study Summary
OCCLUDE is a prospective, post-approval, open-label, single arm, multi-center US registry of patients who undergo embolization with Obsidio™ Conformable Embolic. The purpose of this Registry is to assess effectiveness and safety outcomes of subjects who undergo embolization with Obsidio.
Conditions Studied
Interventions
- DEVICE Obsidio™ Conformable Embolic
Study Locations (20)
California
- Ronald Reagan UCLA Medical Center - Los Angeles
- St. Joseph's Medical Center - Stockton
Illinois
- Northwestern Memorial Hospital - Chicago
- University of Chicago Hospital - Chicago
Massachusetts
- Massachusetts General Hospital - Boston
- Beth Israel Deaconess Medical Center - Boston
New York
- Albany Medical Center - Albany
- Mount Sinai Medical Center - New York
Texas
- The University of Texas MD Anderson Cancer Center - Houston
- University of Texas Houston Health Science Center - Houston
Arizona
- Mayo Clinic Hospital - Phoenix
Delaware
- Christiana Hospital - Newark
District of Columbia
- MedStar Georgetown University Hospital - Washington D.C.
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 125 participants |
| Start Date | 2024-06-19 |
| Est. Completion | 2025-09-09 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06170619
The ClinicalTrials.gov registry entry for NCT06170619 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 125 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 1,479-participant average among 23 other Bleeding trials with a reported enrollment target (92% lower). The listed sponsor is Boston Scientific Corporation, which has 280 total studies on file at ClinicalTrials.gov.
The record links to 3 conditions, with Bleeding appearing as the primary indexed condition, and to 1 intervention - of which Obsidio™ Conformable Embolic is the first listed.
NCT06170619 reports 20 study locations spanning 15 distinct geographic areas - top geographies include California, Illinois, Massachusetts.
Frequently Asked Questions
What is clinical trial NCT06170619 about?
NCT06170619 is a clinical study titled "Obsidio™ Conformable Embolic Registry". OCCLUDE is a prospective, post-approval, open-label, single arm, multi-center US registry of patients who undergo embolization with Obsidio™ Conformable Embolic. The purpose of this Registry is to assess effectiveness and safety outcomes of subjects who undergo embolization with Obsidio.
What is the current status of trial NCT06170619?
This trial is currently completed. The enrollment target is 125 participants. The study started on 2024-06-19. Estimated completion is 2025-09-09.
What conditions does trial NCT06170619 study?
This clinical trial studies the following conditions: Bleeding, Hemorrhage, Hypervascular Tumors.
What interventions are being tested in trial NCT06170619?
The interventions under investigation include: Obsidio™ Conformable Embolic (DEVICE).
Who is sponsoring clinical trial NCT06170619?
This trial is sponsored by Boston Scientific Corporation, which has 280 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06170619 being conducted?
This trial has 20 study locations across Arizona, California, Delaware, District of Columbia, Georgia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Bleeding
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Preoperative Tranexamic Acid (TXA) to Prevent Bleeding in Patients Undergoing Major Colorectal Surgery
RECRUITING · Phase 2
-
The Neonatal Hemorrhagic Risk Assessment in Thrombocytopenia
RECRUITING
-
Quantra Point-of-Care Hemostasis Monitoring
RECRUITING · NA
-
Aspirin and Hemocompatibility Events in Chronic Advanced Heart Failure Patients With Assist Device
RECRUITING · Phase 4
-
Anticoagulation for New-Onset Post-Operative Atrial Fibrillation After CABG
RECRUITING · Phase 3
-
Impact of IV Iron on Bleeding Symptoms in Iron Deficient Patients With Inherited Bleeding Disorders
RECRUITING
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.